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1. Introduction 
The energy demand of the brain is very large: it accounts for 20% of the body’s energy 
consumption, even though its weight is less than 2% of the total body mass. In the adult, 
brain energy comes primarily from glucose through oxidative glycolysis.  The end product 
is acetyl-coenzyme A (acetyl-CoA), which enters the mitochondria and feeds into the 
tricarboxylic acid (TCA) cycle to produce energy in the form of reductants, such as NADH. 
The chemical energy of NADH is then used by the respiratory chain, or electron transport 
chain, to synthesize ATP (Fig. 1). Energy depletion is a major factor in the cascade of events 
culminating in dopaminergic neuronal death in Parkinson’s disease (PD). There are two 
reasons for that. First, a frequent feature of the disease, as well as of other 
neurodegenerative diseases, is an alteration of glucose metabolism. Second, there is a 
decrease of mitochondrial respiratory chain activity due to, in particular, inhibition of the 
electron transport system complex I (NADH-ubiquinone oxidoreductase).  
Complex I activity is redox-dependent and thiol-regulated; therefore its inhibition is 
associated with oxidative stress. Depletion of GSH, a major antioxidant and redox 
modulator, is observed in the substantia nigra of parkinsonian patients, as well as in the 
mouse MPTP model of the disease. Conversely, the restoration of GSH levels preserves 
complex I activity. Accordingly, the maintenance of cellular redox homeostasis by thiol 
agents protects against nigrostriatal toxicity. 
In the case of the alteration of glucose metabolism, the brain has the ability to adapt its 
metabolism and to increase its reliance on lipids for energy production, through fatty acid β-
oxidation. The process involves a mitochondrial oxido-reductase superfamily with broad 
substrate specificity.  The penultimate step of the process is catalyzed by L-3-hydroxyacyl-
CoA dehydrogenase (HADH II) (EC 1.1.1.35). HADH II overexpression protects against 
acute brain injury and chronic neurodegeneration. By-products of fatty acid β−oxidation are 
the ketone bodies β-hydroxybutyrate and acetoacetate. When injected into mice or rats, or 
administered in the form of a ketogenic diet, ketone bodies have a protective role in a broad 
spectrum of cerebral injuries and diseases. 
In the present report, we examine the brain energy metabolism, its alterations associated 
with PD and how fatty acid β-oxidation can compensate such impairment. Energy store 
boosting agents have potential therapeutic properties. Pantethine, the precursor of vitamin 
www.intechopen.com
  
Etiology and Pathophysiology of Parkinson's Disease 
 
274 
B5, is one of them, with the advantage of targeting multiple pathways involved in disease 
process. By itself or by its constituents (Fig. 2), pantethine regulates lipid metabolism, in 
addition to its anti-oxidant and anti-inflammatory properties, giving rise to the promise of 
an original therapeutic strategy against PD. 
 
 
Fig. 1. The energetic pathways. Glycolysis is the major energetic pathway in the adult brain. It is 
impaired in Parkinson’s disease, leading to an energy crisis, which is compensated by fatty acid-
β−oxidation. Solid symbols (red) indicate the injuries and alterations occurring in the processes 
leading to the disease; open symbols (green) indicate the protective effects of pantethine. 
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Fig. 2. Pantethine forms the active moiety of CoA. Pantetheine, the reduced form of 
pantethine, is first 4’-phosphorylated by pantothenate kinase and then adenylated by 
phosphopantetheine adenylyl transferase (CoaD) to form dephospho-CoA; finally, 
dephospho-CoA is phosphorylated to coenzyme A by the enzyme dephosphocoenzyme A 
kinase (CoaE). Lipids are metabolized as fatty acids linked to the SH group of pantetheine, 
in the form of acyl-CoA thioesters. 
2. Brain energy metabolism 
Although the brain represents only 2% of the body weight, it receives 15% of the cardiac 
output and accounts for 20% of total body oxygen consumption as well as 25% of total body 
glucose utilization. Under physiological conditions, glycolysis is, by far, the major energetic 
pathway in the adult brain. Glucose is broken down in the presence of oxygen, yielding 
pyruvate and lactate.  Evidence accumulated during the past decade supports the notion that 
astrocytes play a pivotal role in the regulation of brain-glucose metabolism, via the so-called 
neuron-astrocyte lactate shuttle (Escartin et al., 2006; Hertz, 2004; Schurr, 2006). Owing to their 
strategic location surrounding cerebral blood capillaries, astrocytes form the first cellular 
barrier encountered by glucose entering the brain parenchyma, which makes them a prevalent 
site of glucose uptake. Blood-borne glucose crosses the vascular endothelial cells and enters 
brain cells through specific hexose transporters of the glucose transporter family (GLUT) 
(McEwen and Reagan, 2004; Vannucci et al., 1997). When the supply of oxygen therefore does 
not match precisely the demand, e.g. during neuronal activation or under pathological 
conditions, glucose may be broken down anaerobically, to produce lactate in order to supply 
energy faster. This process has, however, low energetic efficiency. 
The following step of energy production is the conversion of pyruvate to acetyl-CoA which 
is used by mitochondria, the power house of living cells. Mitochondria produce the 
reductant NADH via the tricarboxilic acid cycle; then the chemical energy of NADH is used 
by the electron transport chain (ETC) to synthesize ATP. Mammalian ETC is composed of 
least 49 individual polypeptides which constitute a series of electron carriers organized in 
four enzymatic complexes plus the ATP synthase machinery. Complex I (NADH 
ubiquinone oxidoreductase) (EC1.6.5.3) is a very large enzymatic set catalyzing the first step 
of the ETC (Saraste, 1999; Schultz and Chan, 2001). The enzyme oxidizes NADH, 
transferring electrons to Ubiquinone (Coenzyme Q, CoQ), a lipid soluble electron carrier 
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embedded in the lipid bilayer of the inner mitochondrial membrane. Complex II (succinate-
ubiquinone oxidoreductase) (EC1.3.5.1), bound to the inner mitochondrial membrane, 
catalyzes the oxidation of succinate to fumarate with the reduction of ubiquinone to 
ubiquinol. Complex III (ubiquinol-cytochrome C oxidoreductase; EC 1.10.2.2) is the 
oligomeric protein complex that transfers electrons from ubiquinol to cytochrome C and 
links proton translocation to this electron transfer by the proton motive Q cycle mechanism 
(Trumpower, 1990). Complex IV (cytochrome C oxidase  (EC 1.9.3.1) is a transmembrane 
protein which receives electrons from cytochrome C and transfers them to one oxygen 
molecule, converting molecular oxygen to water. In the whole process, a transmembrane 
difference of proton electrochemical potential is established that the ATP synthase then uses 
to synthesize ATP. Mitochondrial dysfunction results in a dwindling supply of ATP, a 
failure in maintaining cellular homeostasis and activation of cell death pathways. 
3. Energy crisis in Parkinson’s disease 
PD, Huntington's disease (HD) and Alzheimer's disease (AD) are age-related diseases of 
diverse etiologies, but energy crisis is a common factor. The link between PD and 
mitochondria was first established with the identification of a deficiency in the activity of 
complex I in the substantia nigra of PD patients (Schapira et al., 1989) and it has been then 
confirmed by several authors (see reviews  in (Banerjee et al., 2009; Schapira, 2006)). Complex I 
deficiency was noticed not only in the brain but also in the peripheral tissues of PD patients 
(Krige et al., 1992; Wallace et al., 1992). Whether mitochondrial dysfunction is the cause or 
effect of PD pathogenesis is debatable. However, it is clear that dopaminergic neurons are 
especially susceptible to energy deficit, meaning that mitochondrial dysfunction may underlie 
selective dopaminergic neuro-degeneration in PD (Beal, 2005). 
The seminal discovery that MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) causes PD-
like symptoms in humans (Langston et al., 1983) and the ensuing rapid unraveling of the 
molecular mechanism of its toxicity strongly stimulated the interest of the PD research 
community in the role of mitochondria in PD pathology. MPTP is metabolized to its toxic form 
MPP+ (1-methyl-4-phenylpyridinium ion) by mitochondrial monoamine oxidase (MAO) 
(Chiba et al., 1984), specifically by MAO B (Heikkila et al., 1984) and is rapidly concentrated in 
the mitochondria (Ramsay et al., 1986b). Once accumulated, MPP+ specifically inhibits the 
oxidation of NAD–linked substrates (Nicklas et al., 1985) by blocking the electron transfer 
through the ETC complex I (Ramsay et al., 1986a). It also inhibits the activity of a key TCA 
(tricarboxylic acid) enzyme KGDHC (α-ketoglutarate dehydrogenase complex) thereby 
impairing the ATP synthesis and inducing “energy crisis” in vivo (Mizuno et al., 1988b) and in 
vitro (Mizuno et al., 1988a). The rather selective toxicity of MPP+ to dopaminergic neurons in 
SN (substantia nigra) was explained by the fact that MPP+ is selectively accumulated by the 
dopamine uptake system involving the dopamine transporters (DAT) (Javitch et al., 1985).  
Platelets which also express DAT (Frankhauser et al., 2006) have been shown to accumulate 
MPP+ with high efficiency and suffer from mitochondrial failure as a result of MPP+ exposure 
(Buckman et al., 1988). Human platelets also contain high levels of MAO B and share a number 
of properties with aminergic neurons including receptors, uptake sites and storage granules 
for amine neurotransmitters. As platelets are more available for research than PD brain 
samples or muscle biopsy specimens, they were a natural choice for PD tissue samples in 
earlier studies on the status of complex I in PD. Low complex I activities have been reported in 
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both PD platelet homogenates and mitochondria isolated from PD platelets, although the 
degree of its inhibition varied within a wide range. Other ETC complexes in PD platelets are 
also concerned: complex II (Yoshino et al., 1992), complex II + complex III (Haas et al., 1995), 
and complex IV (Benecke et al., 1993). Several studies showed impaired complex I, II+III, and 
IV activities in PD muscle (Bindoff et al., 1991; Blin et al., 1994; Cardellach et al., 1993); whereas 
no differences were observed in other studies (DiDonato et al., 1993; Mann et al., 1992; 
Reichmann et al., 1994). Similar conflicting results were reported in the ETC in PD 
lymphocytes (Martin et al., 1996; Yoshino et al., 1992). Such inconsistency in the experimental 
data may be explained by significant methodological differences in these studies, e.g. 
difficulties in obtaining the relevant tissue samples, individual variability of PD patients and 
many other factors, as was suggested (Parker et al., 2008). 
Complex I activity is reduced in mitochondria isolated from PD frontal cortex (Keeney et al., 
2006; Parker et al., 2008); it is believed to be an early pathogenic event in PD. Ample data 
strongly suggest that MPTP-induced ETC disruption per se is sufficient to trigger the death 
of nigrostriatal neurons and to cause PD-like symptoms in animals and humans. Thus, 
despite some conflicting results, systemic complex I deficiency might be a predominant 
feature in PD pathogenesis (Banerjee et al., 2009). Accordingly, 1H and 31P magnetic 
resonance spectrometry demonstrated mitochondrial dysfunction in the putamen and 
midbrain of both early and advanced PD subjects, with a bilateral reduction of high-energy 
phosphates; the changes were associated with abnormally elevated lactate levels. In 
contrast, low-energy metabolites such as adenosine diphophosphate and inorganic 
phosphate were within normal ranges. These results provide strong in vivo evidence that 
mitochondrial dysfunction of mesostriatal neurons is a central and persistent phenomenon 
in the pathogenesis cascade of PD which occurs early in the course of the disease (Hattingen 
et al., 2009; Henchcliffe et al., 2008). 
Paraquat and rotenone are other neurotoxins that inhibit mitochondrial complex I activity, 
whereas there are substantial differences in their action (Richardson et al., 2005). Rotenone 
rat models of PD have been developed that reproduce essential biochemical and behavioral 
human PD features (Alam and Schmidt, 2002; Betarbet et al., 2000; Greenamyre et al., 2003; 
Sherer et al., 2003). 
Complex I activity is redox-dependent and thiol-regulated (Annepu and Ravindranath, 
2000; Sriram et al., 1998). Since PD pathogenesis consistently involve reactive oxygen and 
nitrogen species (Bove et al., 2005; Li et al., 2003; Przedborski, 2005; Przedborski and 
Ischiropoulos, 2005) this may explain, at least in part, complex I inhibition. Thus, depletion 
of GSH, an antioxidant and redox modulator, may be one of the early events leading to the 
inhibition of complex I activity and loss of mitochondrial function (Chinta and Andersen, 
2006; Jha et al., 2000). 
4. Mitochondrial dysfunction and the genetic causes of the disease 
In the past decade, a rapidly expanding list of Mendelian-inherited gene mutations has 
provided great insight into the mechanisms leading to loss of the nigrostriatal 
dopaminergic neurons in familial PD which constitutes less than 10% of the total number 
of PD cases. In recent years, a plethora of studies of the multifunctional consequences of 
these mutations point towards the disruption of mitochondrial function culminating in 
neuronal dysfunction and death.  
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α-Synuclein was the first gene associated with familial PD. It was followed by four other 
genes linked conclusively to autosomal recessive (parkin, PINK-1, DJ-1) or dominant 
(LRRK2) Parkinsonism (Bogaerts et al., 2008; Henchcliffe and Beal, 2008). 
PINK1. Mutations in phosphatase and tensin homologue (PTEN)-induced putative kinase 
(PINK1) cause a rare form of autosomal recessive, PD  early onset Parkinsonism following 
the parkin mutations (Valente et al., 2004; Winklhofer and Haass, 2010). Loss of PINK1 
function increases the propensity of cells to oxidative stress-induced cell death and 
imbalance of calcium homeostasis. The experiments suggest that the impairment of 
mitochondrial calcium efflux promotes ROS formation that inhibits glucose uptake, 
resulting in reduced substrate delivery and respiration (Gandhi et al., 2009). 
Parkin is a multifaceted ubiquitin ligase (Moore, 2006). Mutations in the parkin gene serve as 
the most common cause of young onset PD (Farrer et al., 2001; Lucking et al., 2000). Loss of 
function of E3 ligase activity has been suggested to result in accumulation of toxic substrates 
leading to autosomal recessive form of PD (Dawson, 2006). Parkin gene expression is up-
regulated in various stress examples and has a wide range of neuroprotective capacities, 
including protection against mitochondrial dysfunction, endoplasmatic reticulum stress, 
exitotoxicity, proteasome inhibition, and overexpression of α-synuclein, tau, and other 
proteins. Future studies of the biochemical interactions between PINK1 and parkin and 
identification of other components in this pathway are likely to provide insight into PD 
pathogenesis, and might identify new therapeutic targets (Henchcliffe and Beal, 2008).  
DJ-1 and LRRK2. DJ-1 has structural similarities with the stress-inducible Escherichia coli 
chaperone Hsp31 and mutations in the DJ-1 gene are associated with rare cases of early 
onset autosomal recessive PD (Andersen, 2004). The loss of DJ-1 function leads to a striking 
sensitivity to the herbicide paraquat and the insecticide rotenone; this suggests that DJ-1 
may have a role in the protection from oxidative stress caused by environmental toxins. It 
has been clearly demonstrated that, while overexpression of DJ-1 protects neurons from 
oxidative stress-induced damage, conversely DJ-1 deficiency renders cells more susceptible 
to oxidative injury. Mutations in leucin-rich repeat kinase 2 (LRRK2 gene) cause autosomal 
dominant PD (Paisan-Ruiz et al., 2004; Zimprich et al., 2004). The precise physiological role 
of this protein is unknown but the presence of multiple functional domains suggests 
involvement in a wide variety of functions. A possible mechanism of LRRK2 action is at the 
mitochondrial level. 
5. Lipids as an alternative carbon source for energy production 
The brain has the ability to use fatty acids as an alternative carbon source. Fatty acid β-
oxidation parallels glycolysis (Fig. 1). This occurs normally during embryonic development 
and, in adults, under conditions of inadequate glucose supply or increased energy demand, 
as well as under pathological conditions, such as neurodegeneration, hypoxia/ischemia and 
traumatic brain injury (Prins, 2008). 
5.1 Lipid metabolism and regulation of mitochondrial function 
Peroxisome Proliferator-Activated Receptors (PPARs) regulate development, tissue 
differentiation, inflammation, wound healing, mitochondrial function, lipid and glucose 
metabolism (Reddy et al., 2006; Reddy, 2001). PPARs are expressed in CNS neurons and 
astrocytes, raising the possibility of exploring the neuroprotective efficacy of PPAR agonists 
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in several neurodegenerative disorders (Bordet et al., 2006; Heneka and Landreth, 2007; 
Woods et al., 2003). Gene-knockout experiments have revealed that, consistent with their 
distinct expression patterns, each PPAR subtype performs a specific function in fatty acid 
homeostasis. PPAR-α targets genes function together to coordinate the complex metabolic 
changes necessary to conserve energy during fasting and feeding in cases where catabolic 
enzymes promote fatty acid β−oxidation.  
It is now well established that damage to dopaminergic neurons involves oxidative stress, 
microglial activation-mediated inflammation and mitochondrial impairment, which 
ultimately culminate in activation of an apoptotic pathway. The PPAR-γ agonist 
pioglitazone was shown to exert protective effects in a mouse model of PD; it attenuated the 
MPTP intoxication-induced glial activation and prevented dopaminergic cell loss in the 
substantia nigra pars compacta (Breidert et al., 2002). These findings were paralleled by 
another study showing that the treatment with pioglitazone may offer an opportunity for 
treatment of PD to slow its progression (Dehmer et al., 2004). 
PPAR-γ coactivator 1α (PGC-1α) is a master regulator of mitochondrial biogenesis and 
respiration (Lehman et al., 2000; Lin et al., 2002; Puigserver et al., 1998; Wu et al., 1999). It 
transduces many physiological stimuli into specific metabolic programs, often by 
stimulating mitochondrial activity. For example, PGC-1α regulates both β−oxidation of 
fatty acids and gluconeogenesis in liver (Herzig et al., 2001; Puigserver et al., 2003; Rhee 
et al., 2003; Yoon et al., 2001). The importance of PGC-1α in these metabolic programs 
was further revealed through the generation of PGC-1α null mice. These mice display a 
reduced basal expression of many mitochondrial genes in liver, brain, skeletal muscle 
and heart, compared with wild-type animals (Arany et al., 2005; Leone et al., 2005; Lin et 
al., 2004). Moreover, it has been shown that PGC-1α knockout (KO) mice displayed 
neurodegenerative lesions in the brain, particularly in the striatum; the animals also 
showed behavioral abnormalities (Leone et al., 2005; Lin et al., 2004). At present, the 
cause of the brain lesions is unclear, but the lesions observed in many genetic models 
with altered ROS levels raise the possibility that PGC-1α plays an important role in the 
control of ROS in vivo (St-Pierre et al., 2006). PGC-1α and PGC-1β are powerfully 
induced by ROS, and these coactivators, in turn, regulate a complex and multifaceted 
ROS defense system. In the MPTP model, PGC-1α KO mice have a greatly increased 
sensitivity to damage by oxidative stress in the dopaminergic cells of the substantia nigra 
and hippocampal neurons. Conversely, the overexpression of PGC-1α in cultured 
dopaminergic neurons from embryonic rat midbrain resulted in activation of electron 
transport genes and protection against neuronal damage induced by mutant α-synuclein 
(Zheng et al., 2010). The same authors   found   in postmortem brain tissue samples from 
PD patients that the gene sets with the strongest association with PD contained nuclear 
genes encoding subunits of the ETC proteins. These genes all showed decreased 
expression in substantia nigra dopaminergic neurons even in the earliest stages of PD. 
Furthermore, a second gene set associated with PD and also underexpressed in the 
earliest stages of PD encodes enzymes involved in glucose metabolism. These results are 
compelling because many studies have already implicated dysfunctional mitochondria 
and altered energy metabolism as well as defective glucose metabolism in PD. The 
authors realized that these gene sets had in common the master transcriptional regulator, 
PGC-1α and surmised that disruption of PGC-1α expression might be a root cause of PD. 
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5.2 Fatty acid β-oxidation 
As in the case of glycolysis, the end product of fatty acid β-oxidation is acetyl-CoA (Fig. 1) 
which feeds into the TCA cycle to produce energy in the form of NADH and FADH2. The 
enzymes involved in fatty acid β-oxidation all act on acyl-CoA, i.e. fatty acids linked to CoA 
as thioesters. They belong to an oxido-reductase superfamily with broad substrate 
specificity. The enzymes are subdivided into several groups, according to the substrate 
chain length. Each of the constituent steps of the pathway comprises three consecutive 
enzymatic reactions catalyzed by a trifunctional enzymatic complex: 2-enoyl-CoA 
hydratase, 3-hydroxyacyl-CoA dehydrogenase and 3-ketoacyl-CoA thiolase.  The reactions 
yield acetyl-CoA plus a chain-shortened acyl-CoA (at each step, the fatty acid chain loses 
two carbons) (Eaton et al., 2000). 
In the present review, we focus attention on the penultimate step of the process, i.e. acyl-
CoA dehydrogenation. It involves four classes of enzymes: short-chain acyl-CoA 
dehydrogenase (SCAD, active with C4 and C6), medium-chain acyl-CoA dehydrogenase 
(MCAD, active with C4 to C12), long-chain acyl-CoA dehydrogenase (LCAD, active with C8 
to C20) and very-long-chain acyl-CoA dehydrogenase (VLCAD, active with C12 to C24). 
SCAD, MCAD and LCAD are homotetramers located in the mitochondrial matrix. VLCAD, 
however, is a homodimer and is located in the inner mitochondrial membrane. VLCAD is a 
constituent of the trifunctional protein described above. 
Short chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) also known as L-3-hydroxyacyl-
CoA dehydrogenase/amyloid-peptide binding alcohol dehydrogenase (HADH II/ABAD) is 
predominantly a mitochondrial enzyme (Furuta et al., 1997; Kobayashi et al., 1996) that 
belongs to the short-chain dehydrogenase/reductase superfamily (Jornvall et al., 1995). It 
acts on a wide spectrum of substrates, including steroids, cholic acids, and fatty acids, with a 
preference for short chain methyl-branched acyl-CoAs. Abnormally low or high levels of 
SCHAD in certain brain regions may contribute to the pathogenesis of some neural 
disorders. The human SCHAD gene and its protein product are therefore potential targets 
for intervention in conditions such as PD, AD and an X-linked mental retardation, which 
may arise from the impaired degradation of branched fatty acid chains and of isoleucine 
(Yang et al., 2005; Zschocke et al., 2000). 
The levels of SCHAD/HADH II are significantly reduced in the ventral midbrain of both PD 
patients and of a PD mouse model generated by MPTP injection (Przedborski et al., 2004). 
Conversely, transgenic mice with increased expression of human HADH II/ABAD are 
significantly more resistant to MPTP; overexpression of the enzyme mitigates MPTP-
induced impairment of oxidative phosphorylation and ATP production (Tieu et al., 2004). 
This observation suggests that a new way to prevent PD may be to increase expression of 
SCHAD/HADH II in the midbrain. 
6. Therapeutic strategies to target the energy crisis 
6.1 Potential therapeutic compounds 
Coenzyme Q (CoQ) is a component of the electron transport chain where it accepts 
electrons from complexes I and II (Beal, 2004). Its administration increases mitochondrial 
uncoupling protein (UCP) expression in the nervous system of primates, and this is 
associated with marked neuroprotection in both in vitro and in vivo models of MPTP, 
paraquat and rotenone-induced mitochondrial dysfunction. CoQ10 exerts significant 
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protection against MPTP-induced dopamine depletion and loss of tyrosine hydroxylase 
immunoreactive neurons in aged mice (Shults et al., 2002). 
Creatine is a nitrogenous guanidine compound that helps to supply energy to muscle and 
nerve cells (Adhihetty and Beal, 2008). Chronic administration of creatine protects against 
MPTP-induced dopamine loss and improves the survival of neurons in the substantia nigra 
(Matthews et al., 1999). 
α-Lipoic acid (ALA) is a disulfide compound found in mitochondria as a coenzyme for 
pyruvate dehydrogenase and α-ketoglutarate dehydrogenase. Dietary supplementation 
with α-lipoic acid in old rats improved ambulatory activity, decreased oxidative damage, 
and improved mitochondrial function (Hagen et al., 1999). In vitro, pre-treatment of PC12 
cells with R-lipoic acid acts to prevent depletion of GSH content and preserves the 
mitochondrial complex I activity which normally is impaired as a consequence of GSH loss 
(Bharat et al., 2002). 
Carnitine transports long-chain fatty acid into the mitochondrial matrix for subsequent 
β−oxidation (Di Lisa et al., 1985; Rosenthal et al., 1992). Carnitine also facilitates the removal 
of short-chain and medium chain fatty acids that accumulate in the mitochondria during 
normal and abnormal metabolism. Carnitine and acetyl-L-carnitine attenuate neuronal 
damage produced by 3-nitropropionic acid, rotenone, and MPTP in vitro (Snyder et al., 1990; 
Virmani et al., 1995). 
Nicotinamide is a precursor of NADH, a substrate for Complex I (NADH-ubiquinone 
oxidoreductase). It is also an inhibitor of poly-ADP-ribose polymerase, which is activated by 
DNA damage and in turn depletes both NADH and ATP. Activation of poly-ADP-ribose 
polymerase plays a role in neuronal injury induced by both ischemia and MPTP (Eliasson et 
al., 1997; Mandir et al., 1999).  
6.2 Ketone bodies 
If the amounts of acetyl-CoA generated by fatty acid β-oxidation challenge the processing 
capacity of the TCA cycle or if activity in the TCA cycle is low, acetyl-CoA is used in the 
biosynthesis of ketone bodies via β−hydroxy-metylglutaryl-CoA (HMG-CoA) synthesis. The 
main ketone bodies are D-β-hydroxybutyrate (DβHB) and acetoacetate (ACA). They are 
produced by hepatocytes and are transported to the tissues, including the brain; astrocytes 
are also ketogenic, although to a lesser extent (Guzman and Blazquez, 2001). 
DβHB and ACA have a protective role in a broad spectrum of cerebral injuries and diseases 
and they preserve neuronal cell integrity and stability in vitro. The experimental approaches 
used are intravenous infusion of mice or rats with DβHB (Prins, 2008) or administration of a 
ketogenic diet (Maalouf et al., 2009). Exogenous ketone bodies have been employed 
successfully in both rapidly developing pathologies (glutamate excitotoxicity, 
hypoxia/ischemia) and neurodegenerative conditions (PD, AD) [for review see(Prins, 
2008)]. In vitro DβHB prevents neuronal damage induced by glucose deprivation (Izumi et 
al., 1998). Following MPP+ exposure, administration of 4 mmol/L of DβHB increased the 
survival of cultured neurons (Kashiwaya et al., 2000). In the rotenone in vitro model, 
application of 8 mmol/L of DβHB improved mitochondrial membrane potential and 
reduced cytochrome C release by mouse neuronal cultures (Imamura et al., 2006); under the 
same conditions,  cell survival was increased by 60% in human neuroblastoma cell culture. 
In vivo, 24 h infusion of DβHB, using mini-osmotic pumps, protected SNpc dopaminergic 
neurons against MPTP in a dose-dependent and stereospecific manner and prevented the 
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development of PD-like motor abnormalities in mice (Tieu et al., 2003). Tieu’s studies 
provide in vivo and in vitro evidence that DβHB protects not by alleviating MPTP-related 
complex I inhibition, but by enhancing oxidative phosphorylation via a mechanism 
dependent on mitochondrial complex II (succinate-ubiquinone oxidoreductase).  
Therefore, modulation of DβHB levels may be a neuroprotective strategy for the treatment 
of neurodegenerative diseases such as PD. However, the long-term effects of the chronic use 
of DβHB on the cellular metabolism, and especially on mitochondrial function, are not 
known. DβHB has been administered orally for several months to two 6-months-old infants 
with hyperinsulinemic hypoglycemia (Plecko et al., 2002). The high dosage (up to 32 g/d) 
seemed to be tolerated by these patients. In addition, ketogenic diets have been used in 
humans as a treatment for refractory epilepsy. In general, patients tolerate the ketogenic diet 
well with mild side effects (Freeman et al., 2006). However, long-term ketone therapy will 
have to take into consideration possible adverse effects. 
6.3 Pantethine 
A promising emerging therapeutic strategy involves fatty acids combined with pantethine. 
CoA is central in these fields, as illustrated by pantothenate kinase-associated 
neurodegeneration (PKAN). Pantothenate kinase catalyzes pantetheine phosphorylation to 
4’-phosphopantetheine, the first step of CoA synthesis (Fig. 2). PKAN, due to insufficient 
kinase activity, occurs in early adulthood and its symptoms, such as dystonia, rigidity and 
tremor, recall PD and it may lead to PD in late adulthood.  PKAN results in a decrease of 
CoA levels associated with mitochondrial dysfunction. These defects can be reversed by 
pantethine, the oxidized form of pantetheine. Dietary pantethine increased CoA synthesis, 
improved mitochondrial function, rescued brain degeneration, enhanced locomotor abilities, 
and increased lifespan in a Drosophila model of PKAN (Rana et al., 2010). Moreover, 
pantethine circumvented the impairment of fatty acid β-oxidation in rat liver mitochondria 
and microvessels of the brain (Morisaki et al., 1983). It has been shown recently that 
pantethine mitigated MPTP neurotoxicity in the mouse via the enhancement of fatty acid 
β−oxidation, leading to increased levels of circulating ketone bodies and improved 
mitochondrial function (Cornille et al., 2010). In addition, pantethine attenuates MPTP-
induced neuroinflammation, as shown by reduced expression of macrophage antigen-1 
(MAC-1), a critical trigger of microglial activation associated with neurodegeneration (Pei et 
al., 2007) (Fig. 3). Ultimately, pantethine protects from MPTP-induced blood-brain barrier 
(BBB) leakage (Fig. 4) and significantly attenuates the clinical scores (Fig. 5). 
7. Concluding remarks and future perspectives 
Deficits in mitochondrial activity in combination with increased oxidative stress, and aging-
associated damage to mitochondrial DNA are key biochemical abnormalities associated 
with the pathogenesis of not only in sporadic PD but also in familial forms of the disease. 
Factors that trigger these mitochondrial abnormalities are still elusive, however one may 
speculate that strategies aimed at correcting these biochemical abnormalities might be useful 
in halting or slowing down the progression of PD. In this regard some of the candidate 
drugs which showed great efficacy in experimental models of PD have already made it to 
clinical trials. Preliminary clinical trial data on Coenzyme Q10 and creatine have shown 
some promise. There is also a great deal of enthusiasm following the recent identification of 
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novel mitochondrial targets such as PGC-1α and the sirtuin family of enzymes that are 
known to modulate aging, mitochondrial biogenesis, metabolic homeostasis and 
mitochondria-dependent cell death. These observations hold promise for future 
development of neuroprotective strategies in PD by targeting mitochondrial dysfunction. 
However it is important to remember that PD is a multi-factorial disease and mitochondrial 
dysfunction may only be a part of this complex process. Future research should thus focus 
on developing neuroprotective strategies by targeting multiple pathways involved in the 
disease process. Therapeutic approaches targeting both mitochondrial dysfunction and 
oxidative damage in neurodegenerative diseases and aging have great promise (Beal, 2005). 
Pantethine provides an example of molecule able to restore mitochondrial function while 
displaying antioxidant and anti-inflammatory properties. Perhaps, this safe and effective 
compound of natural origin merits consideration for broader use against pathologies such as 
PD. 
 
 
Fig. 3. Attenuation of microglial reaction by pantethine treatment in MPTP-injected mice.  
The figure shows macrophage antigen-1 (Mac-1) immunostaining in SNpc, two days after 
MPTP injection. Microglial reaction was drastically reduced in pantethine-treated mice as 
compared to saline ones. No immunostaining was observed in control animals. 
 
 
Fig. 4. Prevention of BBB leakage by pantethine treatment in MPTP-injected mice.  
Evans blue was administered intravenously on day 16 after MPTP injection. The figure 
shows brains of saline mice with a diffuse dye leakage, and some intensively stained areas. 
In contrast, brains of pantethine-treated mice looked normal, with limited stained areas. 
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Fig. 5. Attenuation of the clinical scores by pantethine treatment in MPTP-injected mice.  
Mice were injected with MPTP and then treated or not treated with pantethine. Under our 
experimental conditions, the scores were 6.2 in both groups 24 hours after MPTP injection 
and they decreased much more rapidly in the pantethine group. (*) Significant difference 
between the two groups, according to the Student t test (p < 0.01). 
8. Acknowledgements 
The authors thank Howard Rickenberg for the critical reading of the manuscript. 
9. References 
Adhihetty, P.J. & Beal, M.F. (2008). Creatine and its potential therapeutic value for targeting 
cellular energy impairment in neurodegenerative diseases. Neuromolecular Medicine, 
Vol.10, pp. 275-290 
Alam, M. & Schmidt, W.J. (2002). Rotenone destroys dopaminergic neurons and induces 
parkinsonian symptoms in rats. behavioural brain research, Vol.136, pp. 317-324 
Andersen, J.K. (2004). Oxidative stress in neurodegeneration: cause or consequence? Nature 
Medicine, Vol.10 Suppl, pp. S18-25 
Annepu, J. & Ravindranath, V. (2000). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-
induced complex I inhibition is reversed by disulfide reductant, dithiothreitol in 
mouse brain. Neuroscience Letters, Vol.289, pp. 209-212 
Arany, Z.; He, H.; Lin, J.; Hoyer, K.; Handschin, C.; Toka, O.; Ahmad, F.; Matsui, T.; Chin, S.; 
Wu, P.H.; Rybkin, II; Shelton, J.M.; Manieri, M.; Cinti, S.; Schoen, F.J.; Bassel-Duby, 
R.; Rosenzweig, A.; Ingwall, J.S.& Spiegelman, B.M. (2005). Transcriptional 
coactivator PGC-1 alpha controls the energy state and contractile function of 
cardiac muscle. Cell Metabolism, Vol.1, pp. 259-271 
Banerjee, R.; Starkov, A.A.; Beal, M.F.& Thomas, B. (2009). Mitochondrial dysfunction in the 
limelight of Parkinson's disease pathogenesis. Biochimica et Biophysica Acta, 
Vol.1792, pp. 651-663 
Beal, M.F. (2004). Therapeutic effects of coenzyme Q10 in neurodegenerative diseases. 
Methods in Enzymology, Vol.382, pp. 473-487 
Beal, M.F. (2005). Mitochondria take center stage in aging and neurodegeneration. Annals of 
Neurology, Vol.58, pp. 495-505 
www.intechopen.com
 The Energy Crisis in Parkinson’s Disease: A Therapeutic Target 
 
285 
Benecke, R.; Strumper, P.& Weiss, H. (1993). Electron transfer complexes I and IV of 
platelets are abnormal in Parkinson's disease but normal in Parkinson-plus 
syndromes. Brain, Vol.116 ( Pt 6), pp. 1451-1463 
Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.& Greenamyre, J.T. 
(2000). Chronic systemic pesticide exposure reproduces features of Parkinson's 
disease. Nature Neuroscience, Vol.3, pp. 1301-1306 
Bharat, S.; Cochran, B.C.; Hsu, M.; Liu, J.; Ames, B.N.& Andersen, J.K. (2002). Pre-treatment 
with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications 
for Parkinson's disease therapy. Neurotoxicology, Vol.23, pp. 479-486 
Bindoff, L.A.; Birch-Machin, M.A.; Cartlidge, N.E.; Parker, W.D., Jr.& Turnbull, D.M. (1991). 
Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's 
disease. Journal of the Neurological Sciences, Vol.104, pp. 203-208 
Blin, O.; Desnuelle, C.; Rascol, O.; Borg, M.; Peyro Saint Paul, H.; Azulay, J.P.; Bille, F.; 
Figarella, D.; Coulom, F.; Pellissier, J.F.& et al. (1994). Mitochondrial respiratory 
failure in skeletal muscle from patients with Parkinson's disease and multiple 
system atrophy. Journal of the Neurological Sciences, Vol.125, pp. 95-101 
Bogaerts, V.; Theuns, J.& van Broeckhoven, C. (2008). Genetic findings in Parkinson's 
disease and translation into treatment: a leading role for mitochondria? Genes, Brain 
and behavior, Vol.7, pp. 129-151 
Bordet, R.; Gele, P.; Duriez, P.& Fruchart, J.C. (2006). PPARs: a new target for 
neuroprotection. Journal of Neurology,  Neurosurgery and Psychiatry, Vol.77, pp. 285-
287 
Bove, J.; Prou, D.; Perier, C.& Przedborski, S. (2005). Toxin-induced models of Parkinson's 
disease. NeuroRx, Vol.2, pp. 484-494 
Breidert, T.; Callebert, J.; Heneka, M.T.; Landreth, G.; Launay, J.M.& Hirsch, E.C. (2002). 
Protective action of the peroxisome proliferator-activated receptor-gamma agonist 
pioglitazone in a mouse model of Parkinson's disease. Journal of Neurochemistry, 
Vol.82, pp. 615-624 
Buckman, T.D.; Chang, R.; Sutphin, M.S.& Eiduson, S. (1988). Interaction of 1-methyl-4-
phenylpyridinium ion with human platelets. Biochemical and Biophysical Research 
Communications, Vol.151, pp. 897-904 
Cardellach, F.; Marti, M.J.; Fernandez-Sola, J.; Marin, C.; Hoek, J.B.; Tolosa, E.& Urbano-
Marquez, A. (1993). Mitochondrial respiratory chain activity in skeletal muscle 
from patients with Parkinson's disease. Neurology, Vol.43, pp. 2258-2262 
Chiba, K.; Trevor, A.& Castagnoli, N., Jr. (1984). Metabolism of the neurotoxic tertiary 
amine, MPTP, by brain monoamine oxidase. Biochemical and Biophysical Research 
Communications, Vol.120, pp. 574-578 
Chinta, S.J. & Andersen, J.K. (2006). Reversible inhibition of mitochondrial complex I 
activity following chronic dopaminergic glutathione depletion in vitro: implications 
for Parkinson's disease. Free Radical Biology and Medicine, Vol.41, pp. 1442-1448 
Cornille, E.; Abou-Hamdan, M.; Khrestchatisky, M.; Nieoullon, A.; de Reggi, M.& Gharib, B. 
(2010). Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and 
circulating ketone body levels by pantethine. Relevance to dopaminergic injury. 
BMC Neuroscience, Vol.11, pp. 51 
Dawson, T.M. (2006). Parkin and defective ubiquitination in Parkinson's disease. Journal of 
Neural Transmission Supplementa, pp. 209-213 
www.intechopen.com
  
Etiology and Pathophysiology of Parkinson's Disease 
 
286 
Dehmer, T.; Heneka, M.T.; Sastre, M.; Dichgans, J.& Schulz, J.B. (2004). Protection by 
pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B 
alpha induction and block of NF kappa B and iNOS activation. Journal of 
Neurochemistry, Vol.88, pp. 494-501 
Di Lisa, F.; Bobyleva-Guarriero, V.; Jocelyn, P.; Toninello, A.& Siliprandi, N. (1985). 
Stabilising action of carnitine on energy linked processes in rat liver mitochondria. 
Biochemical and Biophysical Research Communications, Vol.131, pp. 968-973 
DiDonato, S.; Zeviani, M.; Giovannini, P.; Savarese, N.; Rimoldi, M.; Mariotti, C.; Girotti, F.& 
Caraceni, T. (1993). Respiratory chain and mitochondrial DNA in muscle and brain 
in Parkinson's disease patients. Neurology, Vol.43, pp. 2262-2268 
Eaton, S.; Bursby, T.; Middleton, B.; Pourfarzam, M.; Mills, K.; Johnson, A.W.& Bartlett, K. 
(2000). The mitochondrial trifunctional protein: centre of a beta-oxidation 
metabolon? Biochemical Society Transactions, Vol.28, pp. 177-182 
Eliasson, M.J.; Sampei, K.; Mandir, A.S.; Hurn, P.D.; Traystman, R.J.; Bao, J.; Pieper, A.; 
Wang, Z.Q.; Dawson, T.M.; Snyder, S.H.& Dawson, V.L. (1997). Poly(ADP-ribose) 
polymerase gene disruption renders mice resistant to cerebral ischemia. Nature 
Medicine, Vol.3, pp. 1089-1095 
Escartin, C.; Valette, J.; Lebon, V.& Bonvento, G. (2006). Neuron-astrocyte interactions in the 
regulation of brain energy metabolism: a focus on NMR spectroscopy. Journal of 
Neurochemistry, Vol.99, pp. 393-401 
Farrer, M.; Chan, P.; Chen, R.; Tan, L.; Lincoln, S.; Hernandez, D.; Forno, L.; Gwinn-Hardy, 
K.; Petrucelli, L.; Hussey, J.; Singleton, A.; Tanner, C.; Hardy, J.& Langston, J.W. 
(2001). Lewy bodies and parkinsonism in families with parkin mutations. Annals of 
Neurology, Vol.50, pp. 293-300 
Frankhauser, P.; Grimmer, Y.; Bugert, P.; Deuschle, M.; Schmidt, M.& Schloss, P. (2006). 
Characterization of the neuronal dopamine transporter DAT in human blood 
platelets. Neuroscience Letters, Vol.399, pp. 197-201 
Freeman, J.; Veggiotti, P.; Lanzi, G.; Tagliabue, A.& Perucca, E. (2006). The ketogenic diet: 
from molecular mechanisms to clinical effects. Epilepsy Research, Vol.68, pp. 145-180 
Furuta, S.; Kobayashi, A.; Miyazawa, S.& Hashimoto, T. (1997). Cloning and expression of 
cDNA for a newly identified isozyme of bovine liver 3-hydroxyacyl-CoA 
dehydrogenase and its import into mitochondria. Biochimica et Biophysica Acta, 
Vol.1350, pp. 317-324 
Gandhi, S.; Wood-Kaczmar, A.; Yao, Z.; Plun-Favreau, H.; Deas, E.; Klupsch, K.; Downward, 
J.; Latchman, D.S.; Tabrizi, S.J.; Wood, N.W.; Duchen, M.R.& Abramov, A.Y. (2009). 
PINK1-associated Parkinson's disease is caused by neuronal vulnerability to 
calcium-induced cell death. Molecular Cell, Vol.33, pp. 627-638 
Greenamyre, J.T.; Betarbet, R.& Sherer, T.B. (2003). The rotenone model of Parkinson's 
disease: genes, environment and mitochondria. Parkinsonism and Related Disorders, 
Vol.9 Suppl 2, pp. S59-64 
Guzman, M. & Blazquez, C. (2001). Is there an astrocyte-neuron ketone body shuttle? Trends 
Endocrinol Metab, Vol.12, pp. 169-173 
Haas, R.H.; Nasirian, F.; Nakano, K.; Ward, D.; Pay, M.; Hill, R.& Shults, C.W. (1995). Low 
platelet mitochondrial complex I and complex II/III activity in early untreated 
Parkinson's disease. Annals of Neurology, Vol.37, pp. 714-722 
www.intechopen.com
 The Energy Crisis in Parkinson’s Disease: A Therapeutic Target 
 
287 
Hagen, T.M.; Ingersoll, R.T.; Lykkesfeldt, J.; Liu, J.; Wehr, C.M.; Vinarsky, V.; Bartholomew, 
J.C.& Ames, A.B. (1999). (R)-alpha-lipoic acid-supplemented old rats have 
improved mitochondrial function, decreased oxidative damage, and increased 
metabolic rate. Faseb Journal, Vol.13, pp. 411-418 
Hattingen, E.; Magerkurth, J.; Pilatus, U.; Mozer, A.; Seifried, C.; Steinmetz, H.; Zanella, F.& 
Hilker, R. (2009). Phosphorus and proton magnetic resonance spectroscopy 
demonstrates mitochondrial dysfunction in early and advanced Parkinson's 
disease. Brain, Vol.132, pp. 3285-3297 
Heikkila, R.E.; Manzino, L.; Cabbat, F.S.& Duvoisin, R.C. (1984). Protection against the 
dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by 
monoamine oxidase inhibitors. Nature, Vol.311, pp. 467-469 
Henchcliffe, C. & Beal, M.F. (2008). Mitochondrial biology and oxidative stress in Parkinson 
disease pathogenesis. Nature Clinical Practive Neurology, Vol.4, pp. 600-609 
Henchcliffe, C.; Shungu, D.C.; Mao, X.; Huang, C.; Nirenberg, M.J.; Jenkins, B.G.& Beal, M.F. 
(2008). Multinuclear magnetic resonance spectroscopy for in vivo assessment of 
mitochondrial dysfunction in Parkinson's disease. Annals of the New York Academy of 
Sciences, Vol.1147, pp. 206-220 
Heneka, M.T. & Landreth, G.E. (2007). PPARs in the brain. Biochimica et Biophysica Acta, 
Vol.1771, pp. 1031-1045 
Hertz, L. (2004). The astrocyte-neuron lactate shuttle: a challenge of a challenge. Journal of 
Cerebral Blood Flow and Metabolism, Vol.24, pp. 1241-1248 
Herzig, S.; Long, F.; Jhala, U.S.; Hedrick, S.; Quinn, R.; Bauer, A.; Rudolph, D.; Schutz, G.; 
Yoon, C.; Puigserver, P.; Spiegelman, B.& Montminy, M. (2001). CREB regulates 
hepatic gluconeogenesis through the coactivator PGC-1. Nature, Vol.413, pp. 179-
183 
Imamura, K.; Takeshima, T.; Kashiwaya, Y.; Nakaso, K.& Nakashima, K. (2006). D-beta-
hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of 
Parkinson's disease. Journal of Neuroscience Research, Vol.84, pp. 1376-1384 
Izumi, Y.; Ishii, K.; Katsuki, H.; Benz, A.M.& Zorumski, C.F. (1998). beta-Hydroxybutyrate 
fuels synaptic function during development. Histological and physiological 
evidence in rat hippocampal slices. Journal of Clinical Investigation, Vol.101, pp. 
1121-1132 
Javitch, J.A.; D'Amato, R.J.; Strittmatter, S.M.& Snyder, S.H. (1985). Parkinsonism-inducing 
neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the 
metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective 
toxicity. Proceedings of the National Academy of Sciences of the U S A, Vol.82, pp. 2173-
2177 
Jha, N.; Jurma, O.; Lalli, G.; Liu, Y.; Pettus, E.H.; Greenamyre, J.T.; Liu, R.M.; Forman, H.J.& 
Andersen, J.K. (2000). Glutathione depletion in PC12 results in selective inhibition 
of mitochondrial complex I activity. Implications for Parkinson's disease. Journal of 
Biological Chemistry, Vol.275, pp. 26096-26101 
Jornvall, H.; Persson, B.; Krook, M.; Atrian, S.; Gonzalez-Duarte, R.; Jeffery, J.& Ghosh, D. 
(1995). Short-chain dehydrogenases/reductases (SDR). Biochemistry, Vol.34, pp. 
6003-6013 
Kashiwaya, Y.; Takeshima, T.; Mori, N.; Nakashima, K.; Clarke, K.& Veech, R.L. (2000). D-
beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's 
www.intechopen.com
  
Etiology and Pathophysiology of Parkinson's Disease 
 
288 
disease. Proceedings of the National Academy of Sciences of the U S A, Vol.97, pp. 5440-
5444 
Keeney, P.M.; Xie, J.; Capaldi, R.A.& Bennett, J.P., Jr. (2006). Parkinson's disease brain 
mitochondrial complex I has oxidatively damaged subunits and is functionally 
impaired and misassembled. J Neurosci, Vol.26, pp. 5256-5264 
Kobayashi, A.; Jiang, L.L.& Hashimoto, T. (1996). Two mitochondrial 3-hydroxyacyl-CoA 
dehydrogenases in bovine liver. J Biochem, Vol.119, pp. 775-782 
Krige, D.; Carroll, M.T.; Cooper, J.M.; Marsden, C.D.& Schapira, A.H. (1992). Platelet 
mitochondrial function in Parkinson's disease. The Royal Kings and Queens 
Parkinson Disease Research Group. Annals of Neurology, Vol.32, pp. 782-788 
Langston, J.W.; Ballard, P.; Tetrud, J.W.& Irwin, I. (1983). Chronic Parkinsonism in humans 
due to a product of meperidine-analog synthesis. Science, Vol.219, pp. 979-980 
Lehman, J.J.; Barger, P.M.; Kovacs, A.; Saffitz, J.E.; Medeiros, D.M.& Kelly, D.P. (2000). 
Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac 
mitochondrial biogenesis. Journal of Clinical Investigation, Vol.106, pp. 847-856 
Leone, T.C.; Lehman, J.J.; Finck, B.N.; Schaeffer, P.J.; Wende, A.R.; Boudina, S.; Courtois, M.; 
Wozniak, D.F.; Sambandam, N.; Bernal-Mizrachi, C.; Chen, Z.; Holloszy, J.O.; 
Medeiros, D.M.; Schmidt, R.E.; Saffitz, J.E.; Abel, E.D.; Semenkovich, C.F.& Kelly, 
D.P. (2005). PGC-1alpha deficiency causes multi-system energy metabolic 
derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. 
PLoS Biolology, Vol.3, pp. e101 
Li, N.; Ragheb, K.; Lawler, G.; Sturgis, J.; Rajwa, B.; Melendez, J.A.& Robinson, J.P. (2003). 
Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing 
mitochondrial reactive oxygen species production. Journal of Biological Chemistry, 
Vol.278, pp. 8516-8525 
Lin, J.; Wu, H.; Tarr, P.T.; Zhang, C.Y.; Wu, Z.; Boss, O.; Michael, L.F.; Puigserver, P.; Isotani, 
E.; Olson, E.N.; Lowell, B.B.; Bassel-Duby, R.& Spiegelman, B.M. (2002). 
Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch 
muscle fibres. Nature, Vol.418, pp. 797-801 
Lin, J.; Wu, P.H.; Tarr, P.T.; Lindenberg, K.S.; St-Pierre, J.; Zhang, C.Y.; Mootha, V.K.; Jager, 
S.; Vianna, C.R.; Reznick, R.M.; Cui, L.; Manieri, M.; Donovan, M.X.; Wu, Z.; 
Cooper, M.P.; Fan, M.C.; Rohas, L.M.; Zavacki, A.M.; Cinti, S.; Shulman, G.I.; 
Lowell, B.B.; Krainc, D.& Spiegelman, B.M. (2004). Defects in adaptive energy 
metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell, Vol.119, 
pp. 121-135 
Lucking, C.B.; Durr, A.; Bonifati, V.; Vaughan, J.; De Michele, G.; Gasser, T.; Harhangi, B.S.; 
Meco, G.; Denefle, P.; Wood, N.W.; Agid, Y.& Brice, A. (2000). Association between 
early-onset Parkinson's disease and mutations in the parkin gene. New England 
Journal of Medicine, Vol.342, pp. 1560-1567 
Maalouf, M.; Rho, J.M.& Mattson, M.P. (2009). The neuroprotective properties of calorie 
restriction, the ketogenic diet, and ketone bodies. Brain Research Reviews, Vol.59, pp. 
293-315 
Mandir, A.S.; Przedborski, S.; Jackson-Lewis, V.; Wang, Z.Q.; Simbulan-Rosenthal, C.M.; 
Smulson, M.E.; Hoffman, B.E.; Guastella, D.B.; Dawson, V.L.& Dawson, T.M. 
(1999). Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 
www.intechopen.com
 The Energy Crisis in Parkinson’s Disease: A Therapeutic Target 
 
289 
2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proceedings of the National 
Academy of Sciences of the U S A, Vol.96, pp. 5774-5779 
Mann, V.M.; Cooper, J.M.; Krige, D.; Daniel, S.E.; Schapira, A.H.& Marsden, C.D. (1992). 
Brain, skeletal muscle and platelet homogenate mitochondrial function in 
Parkinson's disease. Brain, Vol.115 ( Pt 2), pp. 333-342 
Martin, M.A.; Molina, J.A.; Jimenez-Jimenez, F.J.; Benito-Leon, J.; Orti-Pareja, M.; Campos, 
Y.& Arenas, J. (1996). Respiratory-chain enzyme activities in isolated mitochondria 
of lymphocytes from untreated Parkinson's disease patients. Grupo-Centro de 
Trastornos del Movimiento. Neurology, Vol.46, pp. 1343-1346 
Matthews, R.T.; Ferrante, R.J.; Klivenyi, P.; Yang, L.; Klein, A.M.; Mueller, G.; Kaddurah-
Daouk, R.& Beal, M.F. (1999). Creatine and cyclocreatine attenuate MPTP 
neurotoxicity. Experimental Neurology, Vol.157, pp. 142-149 
McEwen, B.S. & Reagan, L.P. (2004). Glucose transporter expression in the central nervous 
system: relationship to synaptic function. European Journal of Pharmacology, Vol.490, 
pp. 13-24 
Mizuno, Y.; Sone, N.; Suzuki, K.& Saitoh, T. (1988a). Studies on the toxicity of 1-methyl-4-
phenylpyridinium ion (MPP+) against mitochondria of mouse brain. Journal of the 
Neurological Sciences, Vol.86, pp. 97-110 
Mizuno, Y.; Suzuki, K.; Sone, N.& Saitoh, T. (1988b). Inhibition of mitochondrial respiration 
by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo. 
Neuroscience Letters, Vol.91, pp. 349-353 
Moore, D.J. (2006). Parkin: a multifaceted ubiquitin ligase. Biochemical Society Transactions, 
Vol.34, pp. 749-753 
Morisaki, N.; Matsuoka, N.; Shirai, K.; Sasaki, N.; Saito, Y.& Kumagai, A. (1983). Effect of 
pantethine on fatty acid oxidation in microvessels of rat brain. Tohoku Journal of 
Experimental Medicine, Vol.141, pp. 41-45 
Nicklas, W.J.; Vyas, I.& Heikkila, R.E. (1985). Inhibition of NADH-linked oxidation in brain 
mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-
methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sciences, Vol.36, pp. 2503-2508 
Paisan-Ruiz, C.; Jain, S.; Evans, E.W.; Gilks, W.P.; Simon, J.; van der Brug, M.; Lopez de 
Munain, A.; Aparicio, S.; Gil, A.M.; Khan, N.; Johnson, J.; Martinez, J.R.; Nicholl, D.; 
Carrera, I.M.; Pena, A.S.; de Silva, R.; Lees, A.; Marti-Masso, J.F.; Perez-Tur, J.; 
Wood, N.W.& Singleton, A.B. (2004). Cloning of the gene containing mutations that 
cause PARK8-linked Parkinson's disease. Neuron, Vol.44, pp. 595-600 
Parker, W.D., Jr.; Parks, J.K.& Swerdlow, R.H. (2008). Complex I deficiency in Parkinson's 
disease frontal cortex. Brain Research, Vol.1189, pp. 215-218 
Pei, Z.; Pang, H.; Qian, L.; Yang, S.; Wang, T.; Zhang, W.; Wu, X.; Dallas, S.; Wilson, B.; 
Reece, J.M.; Miller, D.S.; Hong, J.S.& Block, M.L. (2007). MAC1 mediates LPS-
induced production of superoxide by microglia: the role of pattern recognition 
receptors in dopaminergic neurotoxicity. Glia, Vol.55, pp. 1362-1373 
Plecko, B.; Stoeckler-Ipsiroglu, S.; Schober, E.; Harrer, G.; Mlynarik, V.; Gruber, S.; Moser, E.; 
Moeslinger, D.; Silgoner, H.& Ipsiroglu, O. (2002). Oral beta-hydroxybutyrate 
supplementation in two patients with hyperinsulinemic hypoglycemia: monitoring 
of beta-hydroxybutyrate levels in blood and cerebrospinal fluid, and in the brain by 
in vivo magnetic resonance spectroscopy. Pediatric Research, Vol.52, pp. 301-306 
www.intechopen.com
  
Etiology and Pathophysiology of Parkinson's Disease 
 
290 
Prins, M.L. (2008). Cerebral metabolic adaptation and ketone metabolism after brain injury. 
Journal of Cerebral Blood Flow and Metabolism, Vol.28, pp. 1-16 
Przedborski, S. (2005). Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism 
and Related Disorders, Vol.11 Suppl 1, pp. S3-7 
Przedborski, S. & Ischiropoulos, H. (2005). Reactive oxygen and nitrogen species: weapons 
of neuronal destruction in models of Parkinson's disease. Antioxidants and Redox 
Signaling, Vol.7, pp. 685-693 
Przedborski, S.; Tieu, K.; Perier, C.& Vila, M. (2004). MPTP as a mitochondrial neurotoxic 
model of Parkinson's disease. Journal of Bioenergetics and Biomembranes, Vol.36, pp. 
375-379 
Puigserver, P.; Rhee, J.; Donovan, J.; Walkey, C.J.; Yoon, J.C.; Oriente, F.; Kitamura, Y.; 
Altomonte, J.; Dong, H.; Accili, D.& Spiegelman, B.M. (2003). Insulin-regulated 
hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature, Vol.423, 
pp. 550-555 
Puigserver, P.; Wu, Z.; Park, C.W.; Graves, R.; Wright, M.& Spiegelman, B.M. (1998). A cold-
inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell, 
Vol.92, pp. 829-839 
Ramsay, R.R.; Salach, J.I.; Dadgar, J.& Singer, T.P. (1986a). Inhibition of mitochondrial 
NADH dehydrogenase by pyridine derivatives and its possible relation to 
experimental and idiopathic parkinsonism. Biochemical and Biophysical Research 
Communications, Vol.135, pp. 269-275 
Ramsay, R.R.; Salach, J.I.& Singer, T.P. (1986b). Uptake of the neurotoxin 1-methyl-4-
phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the 
mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochemical and 
Biophysical Research Communications, Vol.134, pp. 743-748 
Rana, A.; Seinen, E.; Siudeja, K.; Muntendam, R.; Srinivasan, B.; van der Want, J.J.; Hayflick, 
S.; Reijngoud, D.J.; Kayser, O.& Sibon, O.C. (2010). Pantethine rescues a Drosophila 
model for pantothenate kinase-associated neurodegeneration. Proceedings of the 
National Academy of Sciences of the U S A, Vol.107, pp. 6988-6993 
Reddy, H.K.; Koshy, S.K.; Wasson, S.; Quan, E.E.; Pagni, S.; Roberts, A.M.; Joshua, I.G.& 
Tyagi, S.C. (2006). Adaptive-outward and maladaptive-inward arterial remodeling 
measured by intravascular ultrasound in hyperhomocysteinemia and diabetes. 
Journal of Cardiovascular Pharmacology and Therapeutics, Vol.11, pp. 65-76 
Reddy, J.K. (2001). Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-
oxidation, PPAR alpha, and steatohepatitis. American Journal of Physiology. 
Gastrointestinal and Liver Physiology, Vol.281, pp. G1333-1339 
Reichmann, H.; Janetzky, B.; Bischof, F.; Seibel, P.; Schols, L.; Kuhn, W.& Przuntek, H. 
(1994). Unaltered respiratory chain enzyme activity and mitochondrial DNA in 
skeletal muscle from patients with idiopathic Parkinson's syndrome. European 
Neurology, Vol.34, pp. 263-267 
Rhee, J.; Inoue, Y.; Yoon, J.C.; Puigserver, P.; Fan, M.; Gonzalez, F.J.& Spiegelman, B.M. 
(2003). Regulation of hepatic fasting response by PPARgamma coactivator-1alpha 
(PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. 
Proceedings of the National Academy of Sciences of the U S A, Vol.100, pp. 4012-4017 
www.intechopen.com
 The Energy Crisis in Parkinson’s Disease: A Therapeutic Target 
 
291 
Richardson, J.R.; Quan, Y.; Sherer, T.B.; Greenamyre, J.T.& Miller, G.W. (2005). Paraquat 
neurotoxicity is distinct from that of MPTP and rotenone. Toxicological Sciences, 
Vol.88, pp. 193-201 
Rosenthal, R.E.; Chanderbhan, R.; Marshall, G.& Fiskum, G. (1992). Prevention of post-
ischemic brain lipid conjugated diene production and neurological injury by 
hydroxyethyl starch-conjugated deferoxamine. Free Radical Biology and Medicine, 
Vol.12, pp. 29-33 
Saraste, M. (1999). Oxidative phosphorylation at the fin de siecle. Science, Vol.283, pp. 1488-
1493 
Schapira, A.H. (2006). Mitochondrial disease. Lancet, Vol.368, pp. 70-82 
Schapira, A.H.; Cooper, J.M.; Dexter, D.; Jenner, P.; Clark, J.B.& Marsden, C.D. (1989). 
Mitochondrial complex I deficiency in Parkinson's disease. Lancet, Vol.1, pp. 1269 
Schultz, B.E. & Chan, S.I. (2001). Structures and proton-pumping strategies of mitochondrial 
respiratory enzymes. Annual Review of Biophysics and Biomolecular Structure, Vol.30, 
pp. 23-65 
Schurr, A. (2006). Lactate: the ultimate cerebral oxidative energy substrate? Journal of 
Cerebral Blood Flow & Metabolism, Vol.26, pp. 142-152 
Sherer, T.B.; Betarbet, R.; Testa, C.M.; Seo, B.B.; Richardson, J.R.; Kim, J.H.; Miller, G.W.; 
Yagi, T.; Matsuno-Yagi, A.& Greenamyre, J.T. (2003). Mechanism of toxicity in 
rotenone models of Parkinson's disease. J Neurosci, Vol.23, pp. 10756-10764 
Shults, C.W.; Oakes, D.; Kieburtz, K.; Beal, M.F.; Haas, R.; Plumb, S.; Juncos, J.L.; Nutt, J.; 
Shoulson, I.; Carter, J.; Kompoliti, K.; Perlmutter, J.S.; Reich, S.; Stern, M.; Watts, 
R.L.; Kurlan, R.; Molho, E.; Harrison, M.& Lew, M. (2002). Effects of coenzyme Q10 
in early Parkinson disease: evidence of slowing of the functional decline. Archives of 
Neurology, Vol.59, pp. 1541-1550 
Snyder, J.W.; Kyle, M.E.& Ferraro, T.N. (1990). L-carnitine delays the killing of cultured 
hepatocytes by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Archives of 
Biochemistry and Biophysics, Vol.276, pp. 132-138 
Sriram, K.; Shankar, S.K.; Boyd, M.R.& Ravindranath, V. (1998). Thiol oxidation and loss of 
mitochondrial complex I precede excitatory amino acid-mediated 
neurodegeneration. J Neurosci, Vol.18, pp. 10287-10296 
St-Pierre, J.; Drori, S.; Uldry, M.; Silvaggi, J.M.; Rhee, J.; Jager, S.; Handschin, C.; Zheng, K.; 
Lin, J.; Yang, W.; Simon, D.K.; Bachoo, R.& Spiegelman, B.M. (2006). Suppression of 
reactive oxygen species and neurodegeneration by the PGC-1 transcriptional 
coactivators. Cell, Vol.127, pp. 397-408 
Tieu, K.; Perier, C.; Caspersen, C.; Teismann, P.; Wu, D.C.; Yan, S.D.; Naini, A.; Vila, M.; 
Jackson-Lewis, V.; Ramasamy, R.& Przedborski, S. (2003). D-beta-hydroxybutyrate 
rescues mitochondrial respiration and mitigates features of Parkinson disease. 
Journal of Clinical Investigation, Vol.112, pp. 892-901 
Tieu, K.; Perier, C.; Vila, M.; Caspersen, C.; Zhang, H.P.; Teismann, P.; Jackson-Lewis, V.; 
Stern, D.M.; Yan, S.D.& Przedborski, S. (2004). L-3-hydroxyacyl-CoA 
dehydrogenase II protects in a model of Parkinson's disease. Annals of Neurology, 
Vol.56, pp. 51-60 
Trumpower, B.L. (1990). The protonmotive Q cycle. Energy transduction by coupling of 
proton translocation to electron transfer by the cytochrome bc1 complex. Journal of 
Biological Chemistry, Vol.265, pp. 11409-11412 
www.intechopen.com
  
Etiology and Pathophysiology of Parkinson's Disease 
 
292 
Valente, E.M.; Abou-Sleiman, P.M.; Caputo, V.; Muqit, M.M.; Harvey, K.; Gispert, S.; Ali, Z.; 
Del Turco, D.; Bentivoglio, A.R.; Healy, D.G.; Albanese, A.; Nussbaum, R.; 
Gonzalez-Maldonado, R.; Deller, T.; Salvi, S.; Cortelli, P.; Gilks, W.P.; Latchman, 
D.S.; Harvey, R.J.; Dallapiccola, B.; Auburger, G.& Wood, N.W. (2004). Hereditary 
early-onset Parkinson's disease caused by mutations in PINK1. Science, Vol.304, pp. 
1158-1160 
Vannucci, S.J.; Maher, F.& Simpson, I.A. (1997). Glucose transporter proteins in brain: 
delivery of glucose to neurons and glia. Glia, Vol.21, pp. 2-21 
Virmani, M.A.; Biselli, R.; Spadoni, A.; Rossi, S.; Corsico, N.; Calvani, M.; Fattorossi, A.; De 
Simone, C.& Arrigoni-Martelli, E. (1995). Protective actions of L-carnitine and 
acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or 
inhibitors. Pharmacological Research, Vol.32, pp. 383-389 
Wallace, D.C.; Shoffner, J.M.; Watts, R.L.; Juncos, J.L.& Torroni, A. (1992). Mitochondrial 
oxidative phosphorylation defects in Parkinson's disease. Annals of Neurology, 
Vol.32, pp. 113-114 
Winklhofer, K.F. & Haass, C. (2010). Mitochondrial dysfunction in Parkinson's disease. 
Biochimica et Biophysica Acta, Vol.1802, pp. 29-44 
Woods, J.W.; Tanen, M.; Figueroa, D.J.; Biswas, C.; Zycband, E.; Moller, D.E.; Austin, C.P.& 
Berger, J.P. (2003). Localization of PPARdelta in murine central nervous system: 
expression in oligodendrocytes and neurons. Brain Research, Vol.975, pp. 10-21 
Wu, Z.; Puigserver, P.; Andersson, U.; Zhang, C.; Adelmant, G.; Mootha, V.; Troy, A.; Cinti, 
S.; Lowell, B.; Scarpulla, R.C.& Spiegelman, B.M. (1999). Mechanisms controlling 
mitochondrial biogenesis and respiration through the thermogenic coactivator 
PGC-1. Cell, Vol.98, pp. 115-124 
Yang, S.Y.; He, X.Y.& Schulz, H. (2005). 3-Hydroxyacyl-CoA dehydrogenase and short chain 
3-hydroxyacyl-CoA dehydrogenase in human health and disease. FEBS Journal, 
Vol.272, pp. 4874-4883 
Yoon, J.C.; Puigserver, P.; Chen, G.; Donovan, J.; Wu, Z.; Rhee, J.; Adelmant, G.; Stafford, J.; 
Kahn, C.R.; Granner, D.K.; Newgard, C.B.& Spiegelman, B.M. (2001). Control of 
hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature, 
Vol.413, pp. 131-138 
Yoshino, H.; Nakagawa-Hattori, Y.; Kondo, T.& Mizuno, Y. (1992). Mitochondrial complex I 
and II activities of lymphocytes and platelets in Parkinson's disease. Journal of 
Neural Transmission.Parkinson's disease and Dementia Section, Vol.4, pp. 27-34 
Zheng, B. et al. (2010). PGC-1alpha, a potential therapeutic target for early intervention in 
Parkinson's disease. Science Translational Medicine, Vol.2, pp. 52ra73 
Zimprich, A. et al.(2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism 
with pleomorphic pathology. Neuron, Vol.44, pp. 601-607 
Zschocke, J.; Ruiter, J.P.; Brand, J.; Lindner, M.; Hoffmann, G.F.; Wanders, R.J.& Mayatepek, 
E. (2000). Progressive infantile neurodegeneration caused by 2-methyl-3-
hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched-
chain fatty acid and isoleucine metabolism. Pediatric Research, Vol.48, pp. 852-855 
www.intechopen.com
Etiology and Pathophysiology of Parkinson's Disease
Edited by Prof. Abdul Qayyum Rana
ISBN 978-953-307-462-7
Hard cover, 542 pages
Publisher InTech
Published online 12, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book about Parkinsonâ€™s disease provides a detailed account of etiology and pathophysiology of
Parkinsonâ€™s disease, a complicated neurological condition. Environmental and genetic factors involved in
the causation of Parkinsonâ€™s disease have been discussed in detail. This book can be used by basic
scientists as well as researchers. Neuroscience fellows and life science readers can also obtain sufficient
information. Beside genetic factors, other pathophysiological aspects of Parkinsonâ€™s disease have been
discussed in detail. Up to date information about the changes in various neurotransmitters, inflammatory
responses, oxidative pathways and biomarkers has been described at length. Each section has been written
by one or more faculty members of well known academic institutions. Thus, this book brings forth both clinical
and basic science aspects of Parkinsonâ€™s disease.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Mhamad Abou-Hamdan, Emilie Cornille, Michel Khrestchatisky, Max de Reggi and Bouchra Gharib (2011).
The Energy Crisis in Parkinson’s Disease: A Therapeutic Target, Etiology and Pathophysiology of Parkinson's
Disease, Prof. Abdul Qayyum Rana (Ed.), ISBN: 978-953-307-462-7, InTech, Available from:
http://www.intechopen.com/books/etiology-and-pathophysiology-of-parkinson-s-disease/the-energy-crisis-in-
parkinson-s-disease-a-therapeutic-target
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
